Home › Employers › ImmunoVec, Inc.
ImmunoVec, Inc.: H-1B salaries and sponsorship
ImmunoVec, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $110,000.
Does ImmunoVec, Inc. sponsor H-1B visas?
ImmunoVec, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Feb 20, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| ImmunoVec, Inc. | 2 | $110,000 |
| Computational Biologist | 1 | $110,000 |
| Director, Non-Viral Delivery | 1 | $185,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 3 | $110,000 |
| FY2026 | 1 | $185,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Director, Non-Viral Delivery | $185,000 Level IV | Los Angeles, CA | Feb 20, 2026 | Mar 2, 2026 | Certified |
| Computational Biologist | $110,000 Level III | Los Angeles, CA | Sep 13, 2023 | Oct 1, 2023 | Certified |
| ImmunoVec, Inc. | $110,000 Level III | Los Angeles, CA | Sep 2, 2023 | Oct 1, 2023 | Certified, then withdrawn |
| ImmunoVec, Inc. | $110,000 Level III | Los Angeles, CA | Aug 30, 2023 | Oct 1, 2023 | Withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).